Ivosenib 250 mg (Ivosidenib) – Price, Uses, Side Effects & Where to Buy

Ivosenib 250 mg (Ivosidenib) — Targeted Therapy for IDH1-Mutated Cancers

Generic Name: Ivosidenib

Trade Name: Ivosenib

Strength: 250 mg per tablet

Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Drug Class: IDH1 Inhibitor / Antineoplastic Agent

Prescription Required: Yes — For use only under oncologist supervision

⚠️ Important Notice: Ivosenib 250 mg is a prescription-only oncology medication. It should only be taken under the direct supervision of a licensed oncologist or hematologist. Self-medication is strongly discouraged.

What Is Ivosenib 250 mg?

When someone is diagnosed with a mutation-driven blood cancer, standard chemotherapy doesn’t always tell the full story. Some cancers grow because of a specific genetic defect — and that defect needs a specific answer.

Ivosenib 250 mg is that answer for patients with an IDH1 gene mutation.

The active ingredient, Ivosidenib, is a precision-targeted oral medicine that blocks the IDH1 enzyme — a protein that, when mutated, fuels the growth of certain leukemias and bile duct cancers. According to a peer-reviewed analysis published in PubMed Central, Ivosidenib is the first approved oral, targeted, small-molecule inhibitor of the IDH1 mutation seen in AML — making it a landmark in precision oncology.

Manufactured in Bangladesh by Everest Pharmaceuticals Ltd., Ivosenib offers patients across South Asia and developing nations access to the same class of targeted therapy available globally, at a significantly more accessible price point.

If you are also exploring other blood cancer treatment options available through our platform, you may find our Leukemia treatment category and broader Oncology product range helpful.

What Is Ivosenib Prescribed For?

Your doctor may prescribe Ivosenib if diagnostic testing confirms an IDH1 mutation in your cancer. The two primary conditions it is used for are:

Acute Myeloid Leukemia (AML)

AML is a fast-progressing cancer of the blood and bone marrow. The U.S. National Cancer Institute (NCI) reports that approximately 6% to 10% of patients with AML carry the specific IDH1 mutation — and Ivosidenib was the first FDA-approved treatment to directly target this mutation.

Ivosenib is used in:

• Newly diagnosed AML patients aged 75 years or older who cannot tolerate aggressive chemotherapy
• Patients with relapsed or refractory AML — meaning the cancer has returned or stopped responding to previous treatments

If your oncologist has also discussed other AML-related options, you may want to review Generic Venetoclax 100 mg, another targeted agent used alongside or following AML treatment protocols, available on our platform.

Cholangiocarcinoma (Bile Duct Cancer)

For patients with locally advanced or metastatic bile duct cancer who have received at least one prior line of treatment, Ivosenib offers a targeted oral option when other therapies have stopped working.

Before treatment begins: An approved IDH1 mutation test is required to confirm that Ivosenib is the appropriate therapy for your specific cancer biology.

How Does Ivosenib Work? (Mechanism of Action)

This is where the science becomes genuinely remarkable — and worth understanding as a patient or caregiver.

In patients with an IDH1 mutation, the gene produces a faulty enzyme. That faulty enzyme generates an abnormal compound called 2-hydroxyglutarate (2-HG) inside the cells. Think of 2-HG as a kind of molecular fog — it confuses immature blood cells, stopping them from maturing and causing them to accumulate uncontrollably. That accumulation becomes leukemia.

Research published via the National Institutes of Health (NIH/PMC) confirms that Ivosidenib works by inhibiting IDH1 R132 mutations, lowering 2-hydroxyglutarate levels and inducing myeloid differentiation — essentially allowing leukemia cells to mature normally and reducing blast counts.

In practical terms, Ivosidenib:

1. Binds to the mutant IDH1 enzyme and blocks its activity
2. Lowers 2-HG levels back toward normal range
3. Allows immature cells to differentiate — to mature properly
4. Slows or stops the uncontrolled growth of leukemic cells

This is targeted therapy — and it is fundamentally different from chemotherapy, which broadly attacks all fast-dividing cells in the body.

Dosage and How to Take Ivosenib

Standard Dose: 500 mg once daily (2 tablets of 250 mg taken together)

As documented in the FDA’s official drug approval summary, the recommended Ivosidenib dose is 500 mg orally once daily with or without food, continued until disease progression or unacceptable toxicity. For patients without disease progression, treatment is recommended for a minimum of 6 months to allow time for clinical response.

How to take it correctly:

• Take at the same time each day
• Can be taken with or without food — but avoid high-fat meals close to the time of dosing
• Swallow tablets whole — do not crush, split, or chew
• If you miss a dose and your next scheduled dose is more than 12 hours away, take it as soon as you remember. If it’s within 12 hours of the next dose, skip and continue as normal. Never double up.

Dose adjustments may be needed if you experience significant side effects or are taking certain other medications. Always follow your oncologist’s specific instructions.

What Are the Benefits of Ivosenib for Patients?

For patients who have exhausted first-line options — or who simply cannot tolerate intensive chemotherapy — Ivosenib represents a meaningful clinical step forward.

Oral convenience at home: Unlike IV infusion therapies that require repeated hospital visits, Ivosenib is a daily tablet taken at home. For elderly or frail patients, this is a significant quality-of-life improvement.

Precision over broad toxicity: By targeting a specific genetic mutation rather than all dividing cells, the side-effect profile differs from conventional chemotherapy — and for many patients, it’s more tolerable.

Clinically studied in real trials: A published FDA Approval Summary in PubMed confirmed that in the pivotal trial, the complete remission (CR) + CR with partial hematologic recovery rate was 33% in relapsed/refractory AML patients, with a median duration of response of 8.2 months. More than a third of transfusion-dependent patients achieved transfusion independence.

An option for combination therapy: The NCI reports that in a Phase 3 trial combining Ivosidenib with azacitidine, nearly half of patients achieved complete remission — compared to just 15% on azacitidine alone. Median overall survival was approximately 2 years versus 8 months in the control arm.

Accessible manufacturing: Produced in Bangladesh by Everest Pharmaceuticals, this generic formulation makes IDH1-targeted therapy financially reachable for patients across South Asia.

Side Effects — What Patients Should Know

Ivosenib is generally better tolerated than traditional chemotherapy, but it does carry its own side effect profile.

Commonly Reported Side Effects:

• Nausea, vomiting, or stomach upset
• Diarrhea or constipation
• Fatigue and general tiredness
• Joint or muscle pain
• Reduced appetite
• Mild dizziness or headache

Most of these are manageable and tend to improve with supportive care as your body adjusts to the medication.

Serious Side Effects — Seek Medical Help Immediately:

⚠️ Differentiation Syndrome — This is the most critical risk. It occurs when leukemic cells differentiate too rapidly, triggering a systemic inflammatory response. The FDA’s prescribing guidance for Ivosidenib specifically flags differentiation syndrome as requiring monitoring and prompt clinical response.

Symptoms to watch for:

• Fever (unexplained)
• Difficulty breathing or shortness of breath
• Sudden weight gain (fluid retention)
• Low blood pressure
• Bone pain or swelling

If you or your caregiver notice any of these, contact your oncologist or go to an emergency department immediately. It is treatable when caught early.

QT Prolongation — Ivosenib can affect the electrical rhythm of the heart. A clinical review in PMC noted that QT interval prolongation was observed in 20% of patients in the combination therapy trial. Regular ECG monitoring is a standard part of treatment.

Liver enzyme elevations — Liver function tests are routinely monitored during treatment.

Important Warnings and Precautions

Tell your oncologist before starting Ivosenib if you:

• Have a history of heart rhythm problems
• Have liver or kidney disease
• Are taking any other prescription, over-the-counter, or herbal medications
• Have had a prior allergic reaction to any cancer medication

Pregnancy and Breastfeeding:

Ivosenib can cause serious harm to a developing baby. Women of childbearing age should use effective contraception during treatment and for at least one month after the final dose. Breastfeeding is not recommended during treatment or for at least one month after stopping.

Children and Adolescents:

The safety and effectiveness of Ivosenib in patients under 18 years of age have not been established.

Drug Interactions

Ivosenib is primarily processed by a liver enzyme called CYP3A4. Medications that strongly affect this enzyme can either increase Ivosenib levels (raising side effect risk) or reduce its effectiveness.

Medications to discuss with your doctor:

• Antifungals such as ketoconazole or itraconazole (may increase Ivosenib levels)
• Antibiotics such as rifampicin (may reduce effectiveness)
• Certain anti-seizure medications (phenytoin, carbamazepine)
• Any medication that can prolong QT interval
• St. John’s Wort (herbal supplement)

Always share your complete medication list — including vitamins and herbal products — with your oncologist before starting treatment. For general drug interaction information, MedlinePlus provides a patient-facing Ivosidenib drug reference from the U.S. National Library of Medicine.

How to Store Ivosenib 250 mg

• Store at temperatures below 30°C
• Keep in a cool, dry place away from direct sunlight and humidity
• Store in the original packaging until use
• Keep out of reach of children and pets
• Do not use past the expiry date printed on the pack

Related Cancer Medicines Available at 100Meds

If you or someone in your care is navigating a blood cancer or oncology treatment plan, the following related products on our platform may also be relevant:

• Generic Venetoclax 100 mg — A BCL-2 inhibitor used in CLL and AML, often combined with hypomethylating agents
• Dasanix 20 mg (Dasatinib) — A targeted therapy used in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive AML
• Ibruxen 140 mg (Ibrutinib) — A BTK inhibitor used in CLL and certain lymphomas
• Browse our full Oncology range →

These are complementary products listed for reference only. Treatment selection must always be determined by a qualified oncologist based on individual diagnosis, mutation status, and clinical condition.

Frequently Asked Questions

Q: Is Ivosenib the same as Tibsovo?

Tibsovo is the original branded Ivosidenib developed by Agios Pharmaceuticals (now licensed by Servier). Ivosenib contains the same active ingredient — Ivosidenib 250 mg — and is manufactured by Everest Pharmaceuticals as a generic formulation.

Q: How do I know if my cancer has an IDH1 mutation?

Your oncologist will order a specific IDH1 mutation test before prescribing this medicine. Per the NCI, the FDA also approved a companion diagnostic — the Abbott Real Time IDH1 Assay — specifically for identifying patients who may benefit from Ivosidenib.

Q: Can I take Ivosenib without a prescription?

No. Ivosenib is a prescription-only oncology medication. A licensed oncologist or hematologist must evaluate your condition, confirm IDH1 mutation status, and initiate the prescription.

Q: What is the price of Ivosenib 250 mg?

Pricing varies based on quantity, supply chain, and regional availability. Please use the Inquire Now button or contact us directly via WhatsApp/Telegram for current pricing information tailored to your needs.

Q: Is it safe to order oncology medicines from 100Meds?

100Meds operates as a verified pharmaceutical sourcing platform with documented supply chains. We do not dispense without proper documentation. Contact our team and we will guide you through the process safely and transparently.

A Note to Patients and Caregivers

Receiving a diagnosis of AML or advanced bile duct cancer is a life-altering moment — one that no list of bullet points or drug labels can fully prepare you for. The medical language alone can feel overwhelming.

Ivosenib does not make that path easy. But for patients whose cancer carries an IDH1 mutation, it offers something tangible: a therapy designed around the specific biology of their disease, taken as an oral tablet, now manufactured and accessible in South Asia.

Our team at 100Meds is here to help you access the medication your oncologist has prescribed — with transparency, proper documentation, and genuine care at every step. Reach out to us today.

This page is for informational purposes only and does not constitute medical advice. Ivosenib 250 mg is a prescription medication. Always consult a qualified oncologist before starting, stopping, or adjusting any cancer treatment.